AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
|Articles|July 1, 2014
- BioPharm International-07-01-2014
- Volume 27
- Issue 7
Microbioreactors Increase Productivity
Microbioreactors Increase Productivity
Advertisement
Applikon Biotechnology’s micro-Matrix technology platform for the handling and growth of large numbers of microbial strains, clone libraries, mutant banks, and cells is easy-to-use and cost-effective. The system offers 24 independent bioreactors in a microtiter plate footprint. pH and dissolved oxygen can be controlled in each individual bioreactor via gas and liquid addition. Temperature is controlled individually in each bioreactor by the integrated cooling and heating system. The micro-Matrix offers a scale down of small-scale bioreactors. The bioreactor’s square well cassette design is based upon SBS-format microtiter plates, which integrate into lab automation robots. According to the company, the PC-based interface offers an intuitive interaction for advanced process control in each of the 24 bioreactors.
Applikon Biotechnology
Articles in this issue
over 12 years ago
Benefits and Risks of Drug Information on Social Mediaover 12 years ago
Health Systems Raise the Bar on Reimbursing New Drugsover 12 years ago
Quantitative Mycoplasma DNA Offers Quality Controlover 12 years ago
Moving the Needle on Healthcareover 12 years ago
Analyzing Proteins Using SEC, MALS, and UHPLCover 12 years ago
Brazil's Phytotherapic Drug Market and Regulationover 12 years ago
Industry Seeks Clearer Standards for Track and Traceover 12 years ago
Supplier Audit Program Marks Progressover 12 years ago
Optimizing Human Performance: Part IAdvertisement
Related to this article
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5